Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register

About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.

[1]  R. Peto,et al.  Survival and desferrioxamine in thalassaemia major. , 1982, British medical journal.

[2]  S. Ulijaszek,et al.  What's in a name? Accuracy of using surnames and forenames in ascribing Asian ethnic identity in English populations. , 1986, Journal of epidemiology and community health.

[3]  V. Raleigh,et al.  Public health and the 1991 census , 1994, BMJ.

[4]  Wright,et al.  Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.

[5]  A. Hoffbrand.  Iron chelation therapy. , 2000, Current opinion in hematology.

[6]  J. Stuart,et al.  Smoking, the environment and meningococcal disease: a case control study , 1994, Epidemiology and Infection.

[7]  B. Modell,et al.  The Clinical Approach to Thalassaemia , 1984 .